Clinical review report: Sucroferric Oxyhydroxide (Velphoro) (Vifor Fresenius Medical Care Renal Pharma Ltd.) indication : for the control of serum phosphorus levels in adult patients with end-stage renal disease on dialysis
The objective of this report was to perform a systematic review of the beneficial and harmful effects of sucroferric oxyhydroxide to control serum phosphorus levels in adult patients with end-stage renal disease on dialysis
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
February 2019, 2019
|
| Edition: | Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of sucroferric oxyhydroxide to control serum phosphorus levels in adult patients with end-stage renal disease on dialysis |
|---|---|
| Physical Description: | 1 PDF file (119 pages) illustrations |